JN-2019

N/A

Report date: 2025/01/26 15:59:31

Base Information

Drug NameJN-2019
Drug Alias Nameangiotensin converting enzyme 2 stimulator (JN Nova/NRC)JN-2019
ClassificationBiologics
Mechanisms of ActionAngiotensin-converting enzyme 2 stimulantsCoronavirus spike glycoprotein modulators
TargetsAngiotensin-converting enzyme 2Coronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Renal InsufficiencyRespiratory Distress Syndrome, Adult
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJN Nova Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Research Council CanadaJN Nova Pharma Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Renal InsufficiencyRespiratory Distress Syndrome, Adult
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A